A randomized, double-blind, placebo managed, phase III medical trial evaluated the efficacy and security profile of adalimumab to be a monotherapy in sufferers with RA who had failed to answer csDMARDs [191]. The outcome confirmed both equally statistically significant improvement from the condition action and an excellent basic safety profile. https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/